Scarica l'app Stockscreener
102.48
0.01%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$102.32
Aprire:
$101.78
Volume 24 ore:
33,811
Relative Volume:
0.07
Capitalizzazione di mercato:
$8.06B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-26.28
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
+2.11%
1M Prestazione:
+0.24%
6M Prestazione:
+30.36%
1 anno Prestazione:
+51.87%
Intervallo 1D:
$101.23
$103.70
Intervallo di 1 settimana:
$97.70
$104.11
Portata 52W:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
102.49 | 8.04B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.59 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.18 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
743.08 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.87 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
307.38 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
(NUVL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Growth Value: Should I set a stop loss on Nuvalent IncMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Citigroup Inc. Has $3.04 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Aug Sentiment: Will Nuvalent Inc benefit from green energy policiesWeekly Trading Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - mx.advfn.com
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Nuvalent Executives Sell Shares Under Trading Plan - TradingView
Nuvalent (NUVL) CDO exercises options and sells 5,500 shares under 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CLO sells 5,500 shares after option exercise - Stock Titan
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Cooling And Strong Multi Year Returns - simplywall.st
Nuvalent, Inc. (NUVL) Stock Analysis: A Biotech With A Promising 40.78% Upside Potential - DirectorsTalk Interviews
UBS Adjusts Price Target on Nuvalent to $138 From $132, Maintains Buy Rating - marketscreener.com
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI) - The Globe and Mail
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - AOL.com
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect? - Finviz
Does Nuvalent (NUVL) Have a Chance to Surge by 37.26% According to Wall Street Analysts? - Bitget
Nuvalent (NASDAQ:NUVL) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
Vanguard Group Inc. Raises Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug - Investing.com Australia
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug By Investing.com - Investing.com South Africa
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent (NUVL) targets 2026 launches with ROS1 and ALK lung cancer drugs - Stock Titan
(NUVL) Risk Channels and Responsive Allocation - Stock Traders Daily
Nuvalent (NUVL) details 2025 results and key FDA milestones - Stock Titan
BRIEF-Nuvalent Q4 EPS USD -1.58 - TradingView
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% - The Motley Fool
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 41.94% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
Biotech Fund Trims Nuvalent Stake After 29% Stock Surge - National Today
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Nuvalent (NASDAQ:NUVL) Entering a Key Phase With Nasdaq Index Fund - Kalkine Media
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Trust linked to Nuvalent (NUVL) files Form 144 to sell 1,650 shares - Stock Titan
Bank Watch: Is Nuvalent Inc forming a bullish divergenceMarket Risk Analysis & Fast Gain Swing Alerts - baoquankhu1.vn
(NUVL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans - MarketBeat
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Candriam S.C.A. Purchases 28,462 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing - Yahoo Finance
US Stocks Recap: Is Nuvalent Inc forming a bullish divergenceJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 – Company Announcement - Financial Times
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - PR Newswire
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvalent Inc Azioni (NUVL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Feb 26 '26 |
Option Exercise |
27.85 |
5,500 |
153,175 |
63,617 |
| Noci Darlene | Chief Development Officer |
Feb 26 '26 |
Sale |
103.03 |
5,500 |
566,682 |
58,117 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Option Exercise |
6.89 |
5,500 |
37,895 |
65,134 |
| Miller Deborah Ann | Chief Legal Officer |
Feb 26 '26 |
Sale |
103.05 |
5,500 |
566,788 |
59,634 |
0.02%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):